当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide.

Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide.

Abstract：

:We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II-IV and III-IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Sugita J,Kagaya Y,Miyamoto T,Shibasaki Y,Nagafuji K,Ota S,Furukawa T,Nara M,Akashi K,Taniguchi S,Harada M,Matsuo K,Teshima T,Japan Study Group for Cell Therapy and Transplantation (JSCT).

doi

10.1038/s41409-018-0279-1

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

432-441

issue

3

eissn

0268-3369

issn

1476-5365

pii

10.1038/s41409-018-0279-1

journal_volume

54

pub_type

杂志文章,多中心研究

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation.

    abstract：:The influence of the CFU-GM content of donor marrow on the outcome of allogeneic marrow transplantation (BMT) has been debated. We now report 38 patients (25 acute leukemias, 10 chronic myeloid leukemias, two myeloma; 24 in first CR/CP and 14 in more advanced phases of their disease) undergoing unmanipulated HLA-ident...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bacigalupo A,Piaggio G,Podesta M,Figari O,Benvenuto F,Sogno G,Tedone E,Raffo MR,Grassia L,Ferrero R

    更新日期：1995-02-01 00:00:00

  • Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.

    abstract：:Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable geneti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2011.175

    authors： Gertz MA,Reeder CB,Kyle RA,Ansell SM

    更新日期：2012-09-01 00:00:00

  • Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma.

    abstract：:Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 an...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.318

    authors： Ho J,Yang L,Banihashemi B,Martin L,Halpenny M,Atkins H,Sabloff M,McDiarmid SA,Huebsch LB,Bence-Bruckler I,Giulivi A,Allan DS

    更新日期：2009-02-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract：:Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.74

    authors： Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期：2015-07-01 00:00:00

  • Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

    abstract：:High-risk (HR) multiple myeloma (MM) has poor outcomes with conventional therapy. Tandem autologous-non-myeloablative (NMA) allogeneic stem cell transplantation (autologous stem cell transplantation (ASCT)-NMA allogeneic SCT) is potentially curative secondary to graft-versus-myeloma effect. We retrospectively analysed...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.37

    authors： Nair AP,Walker P,Kalff A,Bergin K,Hocking J,Avery S,Curtis DJ,Patil S,Das T,Klarica D,Morgan S,Muirhead J,Gorniak M,Reynolds J,Spencer A

    更新日期：2017-06-01 00:00:00

  • Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.

    abstract：:It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0301-7

    authors： Yanada M,Masuko M,Mori J,Aoki J,Mizuno S,Fukuda T,Kakihana K,Ozawa Y,Ota S,Kanamori H,Mori T,Nakamae H,Eto T,Shiratori S,Maeda T,Iwato K,Ichinohe T,Kanda Y,Tanaka J,Atsuta Y,Yano S

    更新日期：2019-04-01 00:00:00

  • Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams.

    abstract：:We sent a questionnaire to 22 teams performing allogeneic and autologous bone marrow transplants (BMT) in the UK enquiring about routine use of prophylactic antimicrobials post-transplant, use of CMV-negative blood products and the incidence of major infection acquired more than 3 months post-BMT. Eighteen centres (82...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Hoyle C,Goldman JM

    更新日期：1994-08-01 00:00:00

  • Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.

    abstract：:This study evaluated delivery of involved field radiotherapy (IFRT) with transplantation for lymphomas timed to minimise toxicity. Patients transplanted for lymphoma had infradiaphragmatic disease irradiated pre-transplant and supradiaphragmatic disease post transplant. A total of 31 patients were studied, with a medi...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704759

    authors： Wirth A,Prince HM,Wolf M,Stone JM,Matthews J,Gibson J,Macleod C,Szer J,Grigg A,To B,Roos D,Schwarer AP,Davis S,Australasian Leukaemia and Lymphoma Group.

    更新日期：2005-02-01 00:00:00

  • Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

    abstract：:We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-al...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.320

    authors： Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

    更新日期：2010-07-01 00:00:00

  • Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.

    abstract：:The indolent non-Hodgkin's lymphomas are theoretically curable through allogeneic haematopoietic stem cell transplantation (allo-HSCT). The applicability of standard conditioning allo-HSCT is, however, restricted by its toxicity. Recently, reduced-intensity conditioning regimens have demonstrated efficacy with signifi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703898

    authors： Ho AY,Devereux S,Mufti GJ,Pagliuca A

    更新日期：2003-04-01 00:00:00

  • Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.

    abstract：:BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with ~85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a p...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2014.84

    authors： Bhatia M,Jin Z,Baker C,Geyer MB,Radhakrishnan K,Morris E,Satwani P,George D,Garvin J,Del Toro G,Zuckerman W,Lee MT,Licursi M,Hawks R,Smilow E,Baxter-Lowe LA,Schwartz J,Cairo MS

    更新日期：2014-07-01 00:00:00

  • Early measles vaccination in bone marrow transplant recipients.

    abstract：:Measles vaccination has been recommended after the second year following bone marrow transplant (BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sust...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1704878

    authors： Machado CM,de Souza VA,Sumita LM,da Rocha IF,Dulley FL,Pannuti CS

    更新日期：2005-04-01 00:00:00

  • Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.

    abstract：:Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34(+) cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 10(6) CD34(+) ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.74

    authors： Chen AI,Bains T,Murray S,Knight R,Shoop K,Bubalo J,Fowler C,Slater S,Maziarz RT

    更新日期：2012-12-01 00:00:00

  • Adenovirus infection after pediatric bone marrow transplantation.

    abstract：:Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St Jude Children's Research Hospital between November 1990 and December 1994 identified 6% (seven male, six female) with adenovirus infection. The affected patients had a median age of 7.9 years (range 3-24 years) at tim...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1701563

    authors： Hale GA,Heslop HE,Krance RA,Brenner MA,Jayawardene D,Srivastava DK,Patrick CC

    更新日期：1999-02-01 00:00:00

  • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

    abstract：:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705315

    authors： Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

    更新日期：2006-05-01 00:00:00

  • Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation.

    abstract：:We report a patient who developed a bone and adjacent soft tissue malignancy 22 months after bone marrow transplantation (BMT) for Philadelphia chromosome positive chronic myelogenous leukemia (CML). Concomitant bone marrow was cytologically and cytogenetically normal. Cytogenetic study of tumoral tissue was unsuccess...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Millot F,Facon T,Kerckaert JP,Fenaux P,Lai JL,Parent M,Bauters F,Jouet JP

    更新日期：1991-05-01 00:00:00

  • Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation.

    abstract：:During this study, BalB/C mice were used as recipients and C57 bl/6 mice as donors. Recipients were given 800 cGys of total body irradiation (TBI) on day 0. Transplantation was carried out as follows: group (1): TBI on day 0; group (2): TBI on day 0 and transplantation on day +1; group (3): TBI on day 0 and transplant...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704877

    authors： Mabed M,Maroof S,Zalta K,El-Awadee M

    更新日期：2005-04-01 00:00:00

  • Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.

    abstract：:We report an 11-year old female with myelodysplastic (refractory anemia with excess of blasts) presentation of Fanconi anemia. After failure of initial chemotherapy with low doses of 6-mercaptopurine and prednisolone she underwent allogeneic bone marrow transplantation (BMT) from her HLA-matched sibling. Busulfan 8 mg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700662

    authors： Maschan AA,Kryzanovskii OI,Yourlova MI,Skorobogatova EV,Pashanov ED,Potapova YE,Timonova LA,Bogatcheva NY,Samochatova EV,Roumjantzev AG

    更新日期：1997-02-01 00:00:00

  • Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation.

    abstract：:Reduced sexual function may have negative implications on health related quality of life among lymphoma survivors. A national cross-sectional study among long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplantation auto-SCT treated during 1987-2008 was conducted in 2012-2014. The curr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0745-4

    authors： Bersvendsen HS,Haugnes HS,Dahl AA,Fagerli UM,Fluge Ø,Holte H,Seland M,Wilsgaard T,Smeland KB,Kiserud CE

    更新日期：2020-05-01 00:00:00

  • Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.

    abstract：:We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3+ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initiall...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.89

    authors： Ozyurek E,Cowan MJ,Koerper MA,Baxter-Lowe LA,Dvorak CC,Horn BN

    更新日期：2008-07-01 00:00:00

  • Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.

    abstract：:Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01005-y

    authors： Nagler A,Baron F,Labopin M,Polge E,Esteve J,Bazarbachi A,Brissot E,Bug G,Ciceri F,Giebel S,Gilleece MH,Gorin NC,Lanza F,Peric Z,Ruggeri A,Sanz J,Savani BN,Schmid C,Shouval R,Spyridonidis A,Versluis J,Mohty M

    更新日期：2021-01-01 00:00:00

  • Extensive clonal expansion of T lymphocytes causes contracted diversity of complementarity-determining region 3 and skewed T cell receptor repertoires after allogeneic hematopoietic cell transplantation.

    abstract：:We previously described skewed repertoires of the T cell receptor-beta chain variable region (TCRBV) and the TCR-alpha chain variable region (TCRAV) soon after allogeneic hematopoietic cell transplantation. To determine the characteristics of skewed TCRBV after transplantation, we examined the clonality of T lymphocyt...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702858

    authors： Hirokawa M,Matsutani T,Horiuchi T,Kawabata Y,Kitabayashi A,Yoshioka T,Tsuruta Y,Suzuki R,Miura AB

    更新日期：2001-03-01 00:00:00

  • Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.

    abstract：:Invasive fungal infections (IFI) with substantial mortality constitute an increasing problem among BMT patients. From 1986 to 1996 148 children underwent BMT, and are included in a retrospective analysis of the incidence, risk factors and outcome of IFI. By histopathology or culture-proven IFI (Candida, 10; Aspergillu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702654

    authors： Hovi L,Saarinen-Pihkala UM,Vettenranta K,Saxen H

    更新日期：2000-11-01 00:00:00

  • Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.

    abstract：:Patients undergoing bone marrow transplantation (BMT) have decreased levels of salivary Ig over long periods of time. However, shortly after transplantation, a transient rise of Ig concentration in their saliva gland is detected. In order to trace the origin of this Ig, seven BM donors were immunized with tetanus toxo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Chaushu S,Chaushu G,Garfunkel A,Slavin S,Or R,Yefenof E

    更新日期：1994-12-01 00:00:00

  • Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell

    abstract：:Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cycloph...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0475-7

    authors： Fayard A,Daguenet E,Blaise D,Chevallier P,Labussière H,Berceanu A,Yakoub-Agha I,Socié G,Charbonnier A,Suarez F,Huynh A,Mercier M,Bulabois CE,Lioure B,Chantepie S,Beguin Y,Bourhis JH,Malfuson JV,Clément L,Peffault de

    更新日期：2019-10-01 00:00:00

  • Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

    abstract：:To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etop...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702598

    authors： Kröger N,Zabelina T,Sonnenberg S,Krüger W,Renges H,Stute N,Finkenstein F,Mayer U,Holstein K,Fiedler W,Colberg H,Sonnen R,Kuse R,Braumann D,Metzner B,del Valle F,Erttmann R,Kabisch H,Zander AR

    更新日期：2000-10-01 00:00:00

  • Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

    abstract：:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in pati...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2011.73

    authors： Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

    更新日期：2012-02-01 00:00:00

  • The number of circulating CD34+ blood cells predicts the colony-forming capacity of leukapheresis products in children.

    abstract：:In children, only a few guidelines are available for optimizing peripheral blood progenitor cell (PBPC) harvesting. We analyzed by means of flow cytometry and clonogenic assays 60 harvest products obtained from 20 children by standardized leukapheresis after treatment with chemotherapy and CSF. In addition, 27 fresh b...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Leibundgut K,von Rohr A,Brülhart K,Hirt A,Ischi E,Jeanneret C,Muff J,Ridolfi-Lüthy A,Wagner HP,Tobler A

    更新日期：1995-01-01 00:00:00

  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期：1994-10-01 00:00:00

  • Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.

    abstract：:The cellular immunoincompetence which follows bone marrow transplantation (BMT) allows both primary and reactivation infection with herpes viruses. We report the overall incidence and timing of varicella zoster virus (VZV) infections after BMT, including the clinical course, complications and associated clinical risk ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Han CS,Miller W,Haake R,Weisdorf D

    更新日期：1994-03-01 00:00:00